Market Cap : 264.91 M | Enterprise Value : 171.1 M | P/E (TTM) : 4.29 | P/B : 3.21 |
---|
AVDL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVDL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
vs
industry |
vs
history |
||
---|---|---|---|
Cash-to-Debt | 352.34 |
51% of the 1056 Companies in the Global Biotechnology industry. ( Industry Median: 73.06 vs. AVDL: 352.34 ) Ranked among companies with meaningful Cash-to-Debt only. |
AVDL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 9.51 Max: 352.34 Current: 352.34 |
Equity-to-Asset | 0.34 |
81% of the 770 Companies in the Global Biotechnology industry. ( Industry Median: 0.68 vs. AVDL: 0.34 ) Ranked among companies with meaningful Equity-to-Asset only. |
AVDL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08 Med: 0.53 Max: 0.8 Current: 0.34 |
Interest Coverage | 57.99 |
72% of the 521 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. AVDL: 57.99 ) Ranked among companies with meaningful Interest Coverage only. |
AVDL'
s Interest Coverage Range Over the Past 10 Years
Min: 46.02 Med: 52.01 Max: 57.99 Current: 57.99 |
Piotroski F-Score: 6 |
|
Altman Z-Score: 1.60 |
|
Beneish M-Score: -1.94 |
|
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
vs
industry |
vs
history |
||
---|---|---|---|
Operating Margin % | 35.21 |
98% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -98.02 vs. AVDL: 35.21 ) Ranked among companies with meaningful Operating Margin % only. |
AVDL'
s Operating Margin % Range Over the Past 10 Years
Min: -611.75 Med: -28.65 Max: 58.79 Current: 35.21 |
Net Margin % | 39.41 |
95% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -88.19 vs. AVDL: 39.41 ) Ranked among companies with meaningful Net Margin % only. |
AVDL'
s Net Margin % Range Over the Past 10 Years
Min: -1027.16 Med: -27.32 Max: 39.41 Current: 39.41 |
ROE % | 94.84 |
99% of the 969 Companies in the Global Biotechnology industry. ( Industry Median: -40.23 vs. AVDL: 94.84 ) Ranked among companies with meaningful ROE % only. |
AVDL'
s ROE % Range Over the Past 10 Years
Min: -1111.21 Med: -23.96 Max: 106.97 Current: 94.84 |
ROA % | 26.38 |
98% of the 1062 Companies in the Global Biotechnology industry. ( Industry Median: -32.55 vs. AVDL: 26.38 ) Ranked among companies with meaningful ROA % only. |
AVDL'
s ROA % Range Over the Past 10 Years
Min: -58.85 Med: -12.24 Max: 27.38 Current: 26.38 |
ROC (Joel Greenblatt) % | 2890.38 |
99% of the 1021 Companies in the Global Biotechnology industry. ( Industry Median: -430.94 vs. AVDL: 2890.38 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
AVDL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4050.11 Med: -42.51 Max: 3538.48 Current: 2890.38 |
3-Year Revenue Growth Rate | 115.60 |
98% of the 604 Companies in the Global Biotechnology industry. ( Industry Median: 4.00 vs. AVDL: 115.60 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
AVDL'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.4 Med: 0.8 Max: 181.1 Current: 115.6 |
Charles Brandes 3,308,250 sh (New) Jim Simons 1,144,600 sh (+38.96%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
---|---|---|---|---|---|---|---|---|
Charles Brandes | 2018-03-29 | Add 45.35% | 0.22% | $ 7.13 | -2% | 4,808,493 | ![]() | |
Charles Brandes | 2017-12-31 | New Buy | 0.55% | $8.03 - $11.25 | $ 7.13 | -24% | 3,308,250 | ![]() |
Industry: | Biotechnology » Biotechnology NAICS: 325412 | |
---|---|---|
Compare: | NAS:ARDX, MIL:MLM, NAS:MLNT, NAS:CASI, NAS:ATHX, NAS:CDXC, OSL:BGBIO, XKRX:007630, NAS:NLNK, NAS:CMRX, NAS:FBIO, NAS:CALA, NAS:BLCM, NAS:OCUL, ASX:PNV, AMEX:AMPE, OTCPK:AXIM, ROCO:6586, NAS:NERV, OTCPK:ELOX » details | |
Traded in other countries: | AWK1.Germany, | |
Headquarter Location: | Ireland |
vs
industry |
vs
history |
||
---|---|---|---|
PE Ratio | 4.29 |
91% of the 260 Companies in the Global Biotechnology industry. ( Industry Median: 29.83 vs. AVDL: 4.29 ) Ranked among companies with meaningful PE Ratio only. |
AVDL'
s PE Ratio Range Over the Past 10 Years
Min: 4.22 Med: 11.42 Max: 33.65 Current: 4.29 |
PE Ratio without NRI | 4.29 |
92% of the 255 Companies in the Global Biotechnology industry. ( Industry Median: 30.45 vs. AVDL: 4.29 ) Ranked among companies with meaningful PE Ratio without NRI only. |
AVDL'
s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.22 Med: 11.42 Max: 33.65 Current: 4.29 |
Price-to-Owner-Earnings | 10.47 |
91% of the 148 Companies in the Global Biotechnology industry. ( Industry Median: 36.07 vs. AVDL: 10.47 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. |
AVDL'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.96 Med: 19.07 Max: 537.22 Current: 10.47 |
PB Ratio | 3.21 |
63% of the 954 Companies in the Global Biotechnology industry. ( Industry Median: 4.51 vs. AVDL: 3.21 ) Ranked among companies with meaningful PB Ratio only. |
AVDL'
s PB Ratio Range Over the Past 10 Years
Min: 1.84 Med: 4.76 Max: 71.87 Current: 3.21 |
PS Ratio | 1.69 |
89% of the 733 Companies in the Global Biotechnology industry. ( Industry Median: 9999.00 vs. AVDL: 1.69 ) Ranked among companies with meaningful PS Ratio only. |
AVDL'
s PS Ratio Range Over the Past 10 Years
Min: 1.67 Med: 4.68 Max: 799.47 Current: 1.69 |
Price-to-Operating-Cash-Flow | 18.84 |
88% of the 196 Companies in the Global Biotechnology industry. ( Industry Median: 30.32 vs. AVDL: 18.84 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
AVDL'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.79 Med: 17.68 Max: 49.71 Current: 18.84 |
EV-to-EBIT | 1.83 |
90% of the 262 Companies in the Global Biotechnology industry. ( Industry Median: 24.43 vs. AVDL: 1.83 ) Ranked among companies with meaningful EV-to-EBIT only. |
AVDL'
s EV-to-EBIT Range Over the Past 10 Years
Min: -88.3 Med: -7.1 Max: 89.5 Current: 1.83 |
EV-to-EBITDA | 1.73 |
92% of the 287 Companies in the Global Biotechnology industry. ( Industry Median: 21.70 vs. AVDL: 1.73 ) Ranked among companies with meaningful EV-to-EBITDA only. |
AVDL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -304 Med: -6.6 Max: 76.3 Current: 1.73 |
EV-to-Revenue | 0.99 |
96% of the 777 Companies in the Global Biotechnology industry. ( Industry Median: 13.46 vs. AVDL: 0.99 ) Ranked among companies with meaningful EV-to-Revenue only. |
AVDL'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1 Med: 4.1 Max: 248 Current: 0.99 |
Current Ratio | 1.43 |
80% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 4.21 vs. AVDL: 1.43 ) Ranked among companies with meaningful Current Ratio only. |
AVDL'
s Current Ratio Range Over the Past 10 Years
Min: 0.83 Med: 2.89 Max: 6.76 Current: 1.43 |
Quick Ratio | 1.36 |
77% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 3.92 vs. AVDL: 1.36 ) Ranked among companies with meaningful Quick Ratio only. |
AVDL'
s Quick Ratio Range Over the Past 10 Years
Min: 0.77 Med: 2.83 Max: 6.7 Current: 1.36 |
Days Inventory | 118.40 |
53% of the 498 Companies in the Global Biotechnology industry. ( Industry Median: 126.17 vs. AVDL: 118.40 ) Ranked among companies with meaningful Days Inventory only. |
AVDL'
s Days Inventory Range Over the Past 10 Years
Min: 51.05 Med: 100.4 Max: 1457.72 Current: 118.4 |
Days Sales Outstanding | 31.15 |
64% of the 656 Companies in the Global Biotechnology industry. ( Industry Median: 64.11 vs. AVDL: 31.15 ) Ranked among companies with meaningful Days Sales Outstanding only. |
AVDL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.8 Med: 69.78 Max: 541.87 Current: 31.15 |
Days Payable | 167.42 |
83% of the 456 Companies in the Global Biotechnology industry. ( Industry Median: 62.86 vs. AVDL: 167.42 ) Ranked among companies with meaningful Days Payable only. |
AVDL'
s Days Payable Range Over the Past 10 Years
Min: 161.48 Med: 228.67 Max: 3311.63 Current: 167.42 |
vs
industry |
vs
history |
||
---|---|---|---|
3-Year Average Share Buyback Ratio | 21.20 |
60% of the 768 Companies in the Global Biotechnology industry. ( Industry Median: -13.20 vs. AVDL: 21.20 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
AVDL'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7 Med: -7.8 Max: 21.2 Current: 21.2 |
vs
industry |
vs
history |
||
---|---|---|---|
Price-to-Intrinsic-Value-Projected-FCF | 3.69 | ||
Price-to-Median-PS-Value | 0.36 |
89% of the 614 Companies in the Global Biotechnology industry. ( Industry Median: 1.00 vs. AVDL: 0.36 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
AVDL'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36 Med: 1.09 Max: 16.79 Current: 0.36 |
Earnings Yield (Greenblatt) % | 54.86 |
98% of the 1060 Companies in the Global Biotechnology industry. ( Industry Median: -6.86 vs. AVDL: 54.86 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
AVDL'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28.5 Med: -7.8 Max: 56.1 Current: 54.86 |
Revenue (TTM) (Mil) $ | 173.25 |
---|---|
EPS (TTM) $ | 1.63 |
Beta | 2.39 |
Volatility | 49.67% |
52-Week Range $ | 6.71 - 11.93 |
Shares Outstanding (Mil) | 37.95 (ADR) |
Dec18 | Dec19 | Dec20 | |
---|---|---|---|
Revenue (Mil $) | 118 | 134 | 217 |
EBIT (Mil $) | |||
EBITDA (Mil $) | |||
EPS ($) | -1.30 | -0.75 | 0.50 |
EPS without NRI ($) | -1.30 | -0.75 | 0.50 |
EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
Dividends per Share ($) |
|
GF Chat